

IDS - 08/20/2002



RICHARD E. JENKINS  
JEFFREY L. WILSON  
ARLES A. TAYLOR, JR.  
DAVID P. GLOECKLER  
GREGORY A. HUNT  
JOHN A. LAMERDIN, PH.D.  
BENTLEY J. OLIVE  
E. ERIC MILLS  
CHRISTOPHER P. PERKINS, PH.D.  
\*LICENSED ONLY IN CALIFORNIA

JENKINS & WILSON, P.A.

PATENT ATTORNEYS  
SUITE 1400 UNIVERSITY TOWER  
3100 TOWER BOULEVARD  
DURHAM, NORTH CAROLINA 27707

TELEPHONE (919) 493-8000  
FACSIMILE (919) 419-0383

WEBSITE  
JENKINSANDWILSON.COM

03/01/04 #5 U.S.  
COPY OF PAPERS  
ORIGINALLY FILED

RALEIGH OFFICE

NCSU CENTENNIAL CAMPUS  
VENTURE II SUITE 400  
920 MAIN CAMPUS DRIVE  
RALEIGH, NORTH CAROLINA 27608

TELEPHONE (919) 424-3710  
FACSIMILE (919) 424-3711

August 8, 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. on August 8, 2002

Cathl H. Turner  
Date of Signature:

August 8, 2002

Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. Patent Application Serial No. 10/190,281 for  
ATTACK OF TUMOR CELLS WITH MISSING, LOW OR  
ABERRANT MHC EXPRESSION BY COMBINING NON  
MHC-RESTRICTED T-CELLS/NK-CELLS AND MHC-  
RESTRICTED CELLS  
Our File No. 1406/81

Sir:

Please find enclosed in connection with the subject U.S. patent application the following documents:

1. Information Disclosure Statement (2 pages);
2. Form PTO/SB/08B (in duplicate) (1 page);
3. Copies of cited references (7 references);
4. A return-receipt postcard to be returned to us with the U.S. Patent and Trademark Office filing stamp thereon.

Commissioner for Patents  
Page 2  
August 8, 2002

The Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS & WILSON, P.A.



Richard E. Jenkins  
Registration No. 28,428

REJ/haw/cht

Customer No. Bar Code Label:



Enclosures



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner of Patents, Washington, D.C. 20231 on  
August 8, 2002

Cath H. Turner  
Cath H. Turner  
Date of Signature August 8, 2002

PATENT

COPY OF PAPERS  
ORIGINALLY FILED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schendel et al.

Group Art Unit: Not Assigned

Serial No.: 10/190,281

Examiner: Not Assigned

Filed: July 5, 2002

Docket No. 1406/81

Confirmation No.:

For: ATTACK OF TUMOR CELLS WITH MISSING, LOW OR ABERRANT MHC EXPRESSION BY COMBINING NON MHC-RESTRICTED T-CELL/NK-CELLS AND MHC-RESTRICTED CELLS

\* \* \* \* \*

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the following references. Copies of the references as well as Forms PTO/SB/08A and PTO/SB/08B are attached hereto. This is not to be construed as a representation that a search has been made or that a reference is relevant merely because cited.

- ^ Lifesci 89: 29 815/AN (Abstract zu: Cruse, J.M. et al., EOS-J. Immunol. Immunopharmacol 9 (2), 1989, 41-53)
- ^ Medline 953 54 186/AN (Abstract zu: Baxteranis, C.N. et al., Lancer Immunology, Immunotherapy 40 (6), 1995, 410-8)
- ^ Medline 960 65 257/AN (Abstract zu: Schlebusch, H. et al., Hybridoma 14 (2), 1995, 167-74)
- ^ Medline 920 94 170/AN (Abstract zu: Melief. C.J. et al., Res. Immunol. 142 (5-6), 1991, 425-9)
- Medline 971 32 099/AN (Abstract zu: Leong, G.P., Surgical Clinics of North America 76 (6), 1996, 1355-81)

BEST AVAILABLE COPY

Appn. No.: 190,281

Medline 973 75 563/AN (Abstract zu: Schendel, D.J. et al., J. Mol. Med. 75 (6),  
1997, 400-13)

Medline 940 83 459/AN (Abstract zu: Abe, Y. et al., Lymphocine Cytokine Res.  
12 (5), 1993, 279-83)

Early passage of the subject application to issue is earnestly solicited.


Although it is believed that no fee is due, the Commissioner is hereby authorized  
to charge any deficiencies of payment associated with the filing of this Information  
Disclosure Statement to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS & WILSON, P.A.

Date: August 8, 2002

By:

  
Richard E. Jenkins  
Registration No. 28,428

Suite 1400 University Tower  
3100 Tower Boulevard  
Durham, North Carolina 27707  
Telephone: (919) 493-8000  
Facsimile: (919) 419-0383

Customer No. Bar Code Label:

1406/81 REJ/haw/cbt

Enclosures



AUG 2 0 2002  
PATENT AND TRADEMARK OFFICE

COPY OF PAPERS  
ORIGINALLY FILED

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

**Complete If Known**

Application Number	10/190,281
Filing Date	07/05/2002
First Named Inventor	Dolores Schendel
Group Art Unit	
Examiner Name	
Attorney Docket Number	1406/81

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
KAC	1	CRUSE ET AL., "Immunol Immunopharmacol," Lifesci 89, Vol. 9 (No. 2), p. 41-53, (1989).	
	2	BAXERANIS ET AL., "Lancer Immunology, Immunotherapy," Medline, Vol. 40 (No. 6), p. 410-8, (1995).	
	3	SCHLEBUSCH ET AL., "Hybridoma," Medline, Vol. 14 (No. 2), p. 167-74, (1995).	
	4	MELIEF ET AL., "Res. Immunol," Medline, Vol. 142 (No. 5-6), p. 425-9, (1991).	
	5	G.P. LEONG, "Surgical Clinics of North America," Medline, Vol. 76 (No. 6), p. 1355-81, (1996).	
	6	SCHENDEL ET AL., "Mol. Med.," Medline, Vol. 75 (No. 6), p. 400-13, (1997).	
↓	7	ABE ET AL., "Lymphocine Cytokine Res.," Medline, Vol. 12 (No. 5), p. 279-83, (1993).	

Examiner  
Signature

/Karen A. Canella, Ph.D./

Date  
Considered

06/26/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IDS - 02/11/2003



Connie S. Sheridan  
Signature \_\_\_\_\_  
State of Signature \_\_\_\_\_ Date \_\_\_\_\_

PATENT  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schendel et al.

Group Art Unit: 1633

Serial No.: 10/190,281

Examiner: Not Assigned

Filed: July 5, 2002

Docket No. 1406/81

Confirmation No.: 2506

For: ATTACK OF TUMOR CELLS WITH MISSING, LOW OR ABERRANT MHC EXPRESSION BY COMBINING NON MHC-RESTRICTED T-CELLS/NK-CELLS AND MHC-RESTRICTED CELLS

\* \* \* \* \*

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the documents listed on the attached forms PTO/SB/08A and PTO/SB/08B. Copies of the references as well as Forms PTO/SB/08A and PTO/SB/08B are attached hereto. This is not to be construed as a representation that a search has been made or that a reference is relevant merely because cited.

Early passage of the subject application to issue is earnestly solicited.

Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any deficiencies of payment associated with the filing of this Information Disclosure Statement to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS & WILSON, P.A.

Richard E. Jenkins


Richard E. Jenkins  
Registration No. 28,428

Date: February 11, 2003

By:

Suite 1400 University Tower  
3100 Tower Boulevard

Customer No. Bar Code Label: .



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Substitute for form 1449A/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

She

1

of

1

***Complete if Known***

Application Number	10/190,281
Filing Date	07/05/2002
First Named Inventor	Dolores Schendel
Art Unit	1633
Examiner Name	Unassigned
Attorney Docket Number	1406/81

**RECEIVED**

FEB 21 2003

~~TECH CENTER 1600/2900~~

**Examiner  
Signature**

/Karen A. Canella, Ph.D./


Date Considered

06 / 26 / 2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paper  
control number

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			
(use as many sheets as necessary)			
Sheet	1	of	1
			<b>Application Number</b> 10/190,281
			<b>Filing Date</b> 07/05/2002
			<b>First Named Inventor</b> Dolores Schendel
			<b>Group Art Unit</b> 1633
			<b>Examiner Name</b> Not Assigned
			<b>Attorney Docket Number</b> 1406/81

#### **OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Signature	/Karen A. Canella, Ph.D./	Date Considered	06/26/2006
-----------------------	---------------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.